Dr. Frantz Le Devedec
About Dr. Frantz Le Devedec
Executive Vice President, Research & Product Development
Dr. Frantz Le Devedec serves as the Executive Vice President of Research & Product Development. His role focuses on overseeing the company's research initiatives and product innovation. He brings his extensive experience in biomaterials and drug delivery systems to the forefront, particularly in oncology, pain management, and infectious disease applications.
Expertise in Biomaterials and Drug Delivery
Dr. Le Devedec has accumulated over 15 years of experience in the development of biomaterials and drug delivery systems. His primary focus areas include cancer therapy, pain management, and infectious diseases. His work has continuously pushed the boundaries of scientific research and product development in these fields.
Translational Sciences and Research Leadership
Since 2018, Dr. Le Devedec's leadership in research and translational sciences has been instrumental in transitioning the company from an R&D stage to an international commercial stage. His efforts have been vital in driving the company's strategic initiatives and expanding its market reach.
PhD in Physical Chemistry from Université de Montréal
Dr. Le Devedec earned his PhD in Physical Chemistry from Université de Montréal, graduating with honors. His academic credentials bolster his extensive expertise in the field, laying the groundwork for his successful career in both academia and industry.
Scientific Publications and Patents
Dr. Le Devedec is the first author of over fifteen scientific publications and patents. His contributions to scientific literature and intellectual property continue to underscore his leading role in the field. He also represents the company in international forums, extending its influence and collaborations globally.
Industrial Process for Cannabinoid Extraction in Colombia
Dr. Le Devedec established the company's industrial process for extracting and purifying cannabinoids in Colombia. This development has been a significant milestone for the company, enhancing its capabilities and market offerings in the cannabinoid sector.